LON:IMM ImmuPharma (IMM) Share Price, News & Analysis GBX 12.15 +0.65 (+5.65%) As of 12:30 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesBuy This Stock About ImmuPharma Stock (LON:IMM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ImmuPharma alerts:Sign Up Key Stats Today's Range 10.60▼ 14.4550-Day Range 1.50▼ 17.5152-Week Range 0.85▼ 19.40Volume35.50 million shsAverage Volume8.60 million shsMarket Capitalization£60.72 millionP/E RatioN/ADividend Yield0.77%Price TargetN/AConsensus RatingN/A Company Overview ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. Read More Receive IMM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImmuPharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IMM Stock News HeadlinesWith 80% ownership in ImmuPharma plc (LON:IMM), institutional investors have a lot riding on the businessSeptember 16 at 8:24 AM | finance.yahoo.comImmuPharma (LON:IMM) Trading 28.8% Higher - What's Next?September 15 at 6:25 AM | americanbankingnews.comPrepare for the “Mar-a-Lago Accord” Money ShockWhy Are Wall Street Insiders Moving Their Money to This ONE Asset? Something far more consequential for your money than tariffs is unfolding behind the scenes... Tucked inside this overlooked directive is a plan set to be executed for the first time in in U.S. history. One Stansberry Research's Senior Partner says it's set to trigger a rare window for potentially explosive gains in ONE asset immediately. (Not AI or crypto). Wall Street insiders are already positioning themselves... and he insists you should, too, before it's too late.September 18 at 2:00 AM | Stansberry Research (Ad)ImmuPharma (LON:IMM) Stock Price Up 28.8% - What's Next?September 15 at 4:26 AM | americanbankingnews.comImmuPharma (LON:IMM) Trading 28.8% Higher - Time to Buy?September 15 at 3:51 AM | americanbankingnews.comImmuPharma (LON:IMM) Stock Price Up 18.6% - Should You Buy?September 14, 2025 | americanbankingnews.comImmuPharma (LON:IMM) Trading Up 19.3% - What's Next?September 14, 2025 | americanbankingnews.comSMALL CAP MOVERS: Lupus drug patent lights up the marketSeptember 12, 2025 | msn.comSee More Headlines IMM Stock Analysis - Frequently Asked Questions How have IMM shares performed this year? ImmuPharma's stock was trading at GBX 1.18 at the beginning of 2025. Since then, IMM shares have increased by 931.4% and is now trading at GBX 12.15. How were ImmuPharma's earnings last quarter? ImmuPharma plc (LON:IMM) posted its quarterly earnings data on Wednesday, August, 6th. The company reported ($0.38) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative trailing twelve-month return on equity of 131.41%. How do I buy shares of ImmuPharma? Shares of IMM stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of ImmuPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that ImmuPharma investors own include Castleton Technology (CTP), 4D pharma (DDDD), Motif Bio (MTFB), Thor Energy (THR), Aminex (AEX) and GSK (GSK). Company Calendar Last Earnings8/06/2025Today9/18/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:IMM CIKN/A Webwww.immupharma.org Phone+44-20-71524080FaxN/AEmployees13Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£2.51 million Net Margins3,519.56% Pretax MarginN/A Return on Equity-131.41% Return on Assets-43.00% Debt Debt-to-Equity RatioN/A Current Ratio1.60 Quick Ratio1.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 0.59 per share Price / Cash Flow20.50 Book ValueGBX 0.65 per share Price / Book18.83Miscellaneous Outstanding Shares499,724,000Free FloatN/AMarket Cap£60.72 million OptionableNot Optionable Beta1.53 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (LON:IMM) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredPrepare for the “Mar-a-Lago Accord” Money ShockWhy Are Wall Street Insiders Moving Their Money to This ONE Asset? Something far more consequential for you...Stansberry Research | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmuPharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmuPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
